prolong life, and apparently impairs its quality! On the other hand, in individuals at higher cardiovascular threat receiving statin treatment for a extended time without having adverse reactions, continuation of therapy may be regarded in an effort to steer clear of a possible cardiovascular event. Finally, the opinion from an article by Prof. Banach and Dr. Serban might be cited: “(…) it demands to be emphasised that the accessible information are usually not adequate to draw any direct conclusions or suggestions, and any reduction inside the statin dose or discontinuation must be balanced together with the elevated threat of cardiovascular events” [385].Arch Med Sci 6, October /M. Banach, P. Burchardt, K. Chlebus, P. Dobrowolski, D. Dudek, K. Dyrbu, M. Gsior, P. Jankowski, J. J iak, L. Klosiewicz-Latoszek, I. Kowalska, M. Malecki, A. Prejbisz, M. Rakowski, J. Rysz, B. Solnica, D. Sitkiewicz, G. Sygitowicz, G. Sypniewska, T. Tomasik, A. Windak, D. Zozuliska-Zi kiewicz, B. CybulskaKey POInTS TO ReMeMBeRIn terminally ill individuals and those receiving palliative treatment, data indicate that discontinuation of statin therapy does not enhance the ALK1 Synonyms danger of cardiovascular events and may possibly increase their excellent of life. Hence, in these patients decisions really should be created on a person basis, taking into consideration the patient’s life expectancy and also the prospective to lessen cardiovascular threat with statin therapy, the occurrence of adverse effects and drug interactions with statins and, which must be especially emphasised, the patient’s high-quality of life.10.17. Viral ailments which includes COVID-The coronavirus pandemic laid bare the shortcomings in the Polish healthcare method, showed really weak patient education on well being and, consequently, contributed to significant deterioration of population health in each aspect, specifically in the context of cardiovascular diseases. Observations to date point to several aspects related with worse course of SARS-CoV-2 infection [397]. Probably the most normally reported aspects involve diabetes and obesity [398, 399]. The possibility of cardiovascular events within the course of COVID-19, which includes myocarditis, acute coronary syndrome, or thrombotic complications, is also emphasised. In spite of issues expressed at the starting with the pandemic, no adverse partnership among the use of the renin-angiotensin technique AT1 Receptor review inhibitors as well as the threat of development as well as the course of COVID-19 has been proven [400, 401]. It must be emphasised that certain previous observations indicate that the renin-angiotensin program inhibitors and statins may possibly minimize the danger of death resulting from pneumonia [400]. Study final results also indicate at least neutraleffect of statins on the threat of development and the course of COVID-19. In contrast, the number of studies indicating their quite vital role, improving the prognosis not just in the course of COVID-19, but in addition after recovery, within the socalled Long-Covid period ( 12 weeks just after recovery), is growing [402]. This is linked with all the mechanisms of action of statins, not merely their anti-inflammatory and anti-oxidative properties, stabilising atherosclerotic plaque (specially through the so-called cytokine storm), but in addition inhibition on the principal coronavirus protease, reduction on the availability of lipid structural components in the virus envelope, degradation of so-called viral lipid rafts, or inhibition of its replication [40305]. Some observations indicate possible positive aspects of statins (applied before hospitalisation) around the cou